Global Bio-chem Technology Group Co. Ltd. (HK:0809)
:0809
Want to see HK:0809 full AI Analyst Report?
Top Page
Global Bio-chem Technology Group Co. Ltd.
(0809)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.07
▲(10.00% Upside)
Action:Reiterated
Date:05/15/26
The score is primarily dragged down by weak financial performance—negative equity, high leverage, thin/weak operating profitability, and volatile/negative recent cash flow. Technicals are also soft (negative MACD and below key moving averages). Valuation screens cheap on P/E, but that support is limited given the elevated balance-sheet and cash-flow risk.
Positive Factors
Diversified corn-based product portfolio
The company serves multiple end markets—animal nutrition, food and industrial applications—via corn-derived products. This multi-channel product mix provides structural revenue diversification versus a single end market, supporting resilience if one demand segment softens over several months.
Negative Factors
Negative shareholders' equity
Persistent negative equity is a structural balance-sheet impairment that restricts financial flexibility, undermines lender confidence and limits ability to raise equity or debt on normal terms. Over months this elevates refinancing and covenant risks and constrains strategic investments or capex.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified corn-based product portfolio
The company serves multiple end markets—animal nutrition, food and industrial applications—via corn-derived products. This multi-channel product mix provides structural revenue diversification versus a single end market, supporting resilience if one demand segment softens over several months.
Read all positive factors
Global Bio-chem Technology Group Co. Ltd. (0809) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.07B
Dividend YieldN/A
Average Volume (3M)8.43M
Price to Earnings (P/E)10.8
Beta (1Y)-0.24
Revenue Growth13.86%
EPS Growth-83.41%
CountryHK
Employees1,567
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)<0.01
Shares Outstanding16,832,771,000
10 Day Avg. Volume3,078,640
30 Day Avg. Volume8,433,551
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)-3.27
Price to Sales (P/S)0.74
P/FCF Ratio-59.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model
Company Description
Global Bio-chem Technology Group Company Limited, an investment holding company, manufactures and sells corn refined products and corn-based biochemical products in the People's Republic of China, rest of Asia, the Americas, and internationally. I...
How the Company Makes Money
Global Bio-chem Technology Group primarily makes money by manufacturing and selling corn-derived biochemical products. Its revenue is generated from (1) sales of amino acids (notably lysine) used in animal feed and nutrition, (2) sales of food add...
Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
12
Very Negative
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.28B | 2.00B | 1.37B | 12.71M | 746.55M |
| Gross Profit | 196.44M | 218.68M | 43.64M | -263.37M | 48.35M |
| EBITDA | -1.89M | 16.85M | 4.69B | -469.06M | 785.63M |
| Net Income | 156.30M | 769.60M | 4.22B | -1.44B | -400.80M |
Balance Sheet | |||||
| Total Assets | 4.62B | 4.54B | 5.21B | 5.85B | 6.48B |
| Cash, Cash Equivalents and Short-Term Investments | 94.44M | 85.47M | 315.41M | 41.77M | 109.13M |
| Total Debt | 1.79B | 3.69B | 5.45B | 8.91B | 8.44B |
| Total Liabilities | 5.14B | 6.50B | 9.25B | 13.64B | 13.18B |
| Stockholders Equity | -518.52M | -1.95B | -4.04B | -7.54B | -6.52B |
Cash Flow | |||||
| Free Cash Flow | -28.39M | 76.04M | -94.24M | -94.19M | -501.02M |
| Operating Cash Flow | -7.35M | 76.04M | -50.46M | -88.01M | -475.21M |
| Investing Cash Flow | -21.04M | -535.00K | -14.37M | -413.00K | 392.59M |
| Financing Cash Flow | 33.57M | -76.06M | 112.62M | 109.75M | -48.66M |
Global Bio-chem Technology Group Co. Ltd. Technical Analysis
Negative
0.06
Price Trends
0.06
Negative
0.06
Negative
0.08
Negative
Market Momentum
<0.01
Negative
44.35
Neutral
48.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.35 is Neutral, neither overbought nor oversold. The STOCH value of 48.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0809.
Global Bio-chem Technology Group Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$1.19B | 7.69 | 5.61% | 10.44% | -1.52% | 6.08% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
57 Neutral | HK$330.00M | ― | 3.94% | 0.78% | 6.35% | -52.30% | |
56 Neutral | HK$1.01B | 5.21 | 4.38% | 5.38% | -11.88% | -61.92% | |
46 Neutral | HK$510.42M | -10.82 | -3.25% | 15.38% | 0.78% | -360.00% | |
44 Neutral | HK$1.07B | 10.83 | -11.47% | ― | 13.86% | -83.41% | |
43 Neutral | HK$31.25M | -0.59 | -24.34% | ― | -16.05% | -26.90% |
* Consumer Defensive Sector Average
HK:0809
Global Bio-chem Technology Group Co. Ltd.
0.06
>-0.01
-13.51%
HK:1767
TS Wonders Holding Limited
0.33
0.00
0.00%
HK:2147
Zhengwei Group Holdings Company Limited
0.47
-0.22
-31.62%
HK:2317
Vedan International (Holdings) Ltd.
0.78
0.22
39.29%
HK:3838
China Starch Holdings Limited
0.17
<0.01
1.20%
HK:0829
Shenguan Holdings (Group) Limited
0.16
-0.11
-40.82%
Global Bio-chem Technology Group Co. Ltd. Corporate Events
Global Bio-chem seals coenzyme Q10 production pact with Shenzhou Bio-tech
May 8, 2026
Global Bio-chem Technology Group’s indirect wholly owned subsidiary Changchun Dacheng Dahe Bio-tech Development has signed a cooperation agreement with Shenzhou Bio-tech for the production of coenzyme Q10 mycelium in China. Under the deal, S...
Global Bio-chem Calls 2026 AGM, Seeks Fresh Share Issuance Mandate
Apr 23, 2026
Global Bio-chem Technology Group Company Limited has called its annual general meeting for 24 June 2026 in Hong Kong, where shareholders will review and approve the audited consolidated financial statements and the directors’ and auditorR...
Global Bio-chem Rolls Over RMB34 Million Loan, Extends Guarantee Exposure
Apr 10, 2026
Global Bio-chem Technology Group has disclosed that a loan originally arranged to settle enforcement action against its related party Jinzhou Yuancheng remains outstanding, and the associated financing structure has again been rolled over. Nongfa ...
Global Bio-chem revenue rises but profit slumps on one-off comparisons
Mar 27, 2026
Global Bio-chem Technology Group Company Limited reported a rise in revenue to HK$2.28 billion for the year ended 31 December 2025, up from HK$2.00 billion a year earlier, driven by its corn-based biochemical operations. The group generated gross ...
Global Bio-chem Proposes 10-for-1 Share Consolidation and Larger Board Lot
Mar 27, 2026
Global Bio-chem Technology Group plans a 10-for-1 consolidation of its existing shares and convertible preference shares, raising the par value of each from HK$0.10 to HK$1.00 while keeping the authorised share capital unchanged. The move will sha...
Global Bio-chem Schedules Board Meeting to Approve 2025 Results and Consider Dividend
Mar 17, 2026
Global Bio-chem Technology Group Company Limited has scheduled a board meeting for 27 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.